ClinicalTrials.gg
TerminatedNCT02451540Updated Mar 21, 2018

Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

A Phase 2 interventional study of HRCT scan and Placebo of Roflumilast in Pulmonary Disease, Chronic Obstructive, sponsored by FLUIDDA nv. Terminated at 1 site in Belgium. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2018-03-21.

Sponsored by FLUIDDA nv · Phase 2, Interventional, and Treatment

Why this study was terminated
No new investigational product can be delivered to the site.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
30 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
29th of 32
13 · median 154
Started
2015
the only one that year
Phase 2
4 of 32
none open now
Registered
28th of 32
by date
Lead sponsor
2 of 32
FLUIDDA nv

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 29th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 28th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 30 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

In this study the efficacy of Roflumilast in addition to LAMA/LABA therapy will be assessed using Functional Respiratory Imaging.

In total 40 Chronic obstructive pulmonary disease (COPD) patients, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages C and D, who are stable on LABA/LAMA therapy and who are prone to dynamics hyperinflation will be included in this study. To indicate the susceptibility to dynamics hyperinflation patients should have a baseline Borg Fatigue score after the 6-minute walk test (6MWT) above 4.

The patients will be randomized in such a way that 1 out of 2 patients will receive placebo and 1 the active component.

Image parameters will be assessed and the correlation with lung function and health related quality of life will be checked before and after treatment.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • Pulmonary Disease, Chronic Obstructive
  • dynamics hyperinflation
  • Computed Tomography scan
  • CT scan
  • Functional Respiratory Imaging
  • FRI
  • Roflumilast
  • PRO
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient ≥ 30 years old
  • Written obtained
  • Patient with (BMI) ≥ 20
  • Female patient of who confirm that a method was used at least 14 days before visit 1 and will continue to use a contraception method during the study
  • patient with GOLD stages C and D
  • Patient with a Borg Fatigue score after the 6MWT on screening above 4 to indicate the susceptibility to dynamics hyperinflation
  • Patient with smoking history of at least 10 pack-years
  • Patient takes a combination therapy of LABA/ LAMA at least 6 weeks before visit 1
  • Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Patient with severe immunological diseases and/ or severe acute infectious diseases
  • Patient with heart failure as documented in the medical history or as defined by the investigator during the physical examination performed at visit 1
  • Patient with diagnosis of cancer (except basal cell carcinoma)
  • Patient with a history of depression associated with suicidal ideation or behaviour
  • Patient with moderate or severe hepatic impairment.
  • Patient with lactose intolerance
  • Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.
  • Patient who received inhalation (ICS) within the last 6 weeks prior to the screening visit
  • Patient who received any new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
13 participants (actual)

Study arms

  • Active comparator
    Roflumilast

    Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment

    Radiation: HRCT scan · Drug: Roflumilast

  • Placebo comparator
    Placebo

    Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.

    Radiation: HRCT scan · Drug: Placebo of Roflumilast

Interventions

  • RadiationHRCT scan

    HRCT scan of thorax, at baseline and after 3 months

  • DrugPlacebo of Roflumilast

    Placebo, once a day in the morning during 3 months

    Also known as: Placebo

  • Roflumilast, once a day in the morning during 3 months

    Also known as: Daxas

06

What researchers measure

Primary outcomes

  1. Changes in Airway volume (iVaw)

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  2. Changes in Airway resistance (iRaw)

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  3. Changes in Lobe volumes (iVlobes)

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  4. Changes in Air trapping

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  5. Changes in Internal Lobar Airflow Distribution

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  6. Low Attenuation or Emphysema Score

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  7. Changes in Blood Vessel Density

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

  8. Changes in Airway Wall Thickness

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: 3 months

  9. Aerosol deposition concentrations

    By using Functional Respiratory Imaging the efficacy of Roflumilast in addition to long-acting muscarinic antagonist (LAMA)/ long acting β2-agonist (LABA) therapy will be assessed.

    Time frame: At baseline and after 3 months of treatment

Secondary outcomes

  1. Changes in Spirometry

    Spirometry is a composite outcome measure consisting of the following parameters: * FEV1 * Peak Expiratory Flow (PEF) * Forced Vital Capacity (FVC) * Maximum Expiratory Flow at 50% of FVC (MEF 50) * Maximum Expiratory Flow at 25% of FVC (MEF 25)

    Time frame: At baseline and after 3 months of treatment

  2. Changes in Body plethysmography

    Body plethysmography is a composite outcome measure consisting of the following parameters: * Residual Volume (RV) * TLC * FRC * Airway resistance (Raw)

    Time frame: At baseline and after 3 months of treatment

  3. Changes in Diffusion capacity

    Diffusion capacity is a composite outcome measure consisting of the following parameters: * carbon monoxide transfer factor (TCO) * Alveolar volume (VA)

    Time frame: At baseline and after 3 months of treatment

  4. Changes in 6MWT

    Exercise capacity: distance walked in 6 minutes (m), oxygen saturation measurement will be performed during the test

    Time frame: At baseline and after 3 months of treatment

  5. Changes in Patient Related Outcome (PRO)

    Patient Related Outcome is a composite outcome measure consisting of the following questionnaires: * Borg CR10 Scale: measure of the present dyspnea and leg fatigue before and after exercise * COPD assessment test (CAT): measure of the impact of COPD on your life * Saint George's Respiratory Questionnaire (SGRQ): measure health related quality of life and comfort

    Time frame: At baseline and after 3 months of treatment

07

Study locations

1 site
  • University Hospital of Antwerp
    Edegem, Antwerp 2650, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2015
First posted
May 22, 2015
Start
Sep 2015
Primary completionActual
Aug 31, 2017
CompletionActual
Aug 31, 2017
Last update
Mar 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02451540
Lead sponsor
FLUIDDA nv
Responsible party
Sponsor
First posted
May 22, 2015
Start date
Sep 2015
Primary completion
Aug 31, 2017
Completion
Aug 31, 2017
Last update
Mar 21, 2018

Study contacts

Wilfried De Backer, M.D., M.S.
principal investigator · University Hospital of Antwerp

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion